LULena Uller

Lena Uller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lena Uller has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tezepelumab alters airway epithelial transcriptional responses and epithelial–smooth muscle signalling in uncontrolled asthma

    by Sangeetha Ramu, Sara Vázquez-Mera, Mandy Menzel, Samuel Cerps, Juan José Nieto-Fontarigo, Morten Hvidtfeldt, Celeste Porsbjerg, Asger Sverrild, Lena Uller

    Background: Tezepelumab is a monoclonal antibody that targets thymic stromal lymphopoietin (TSLP). It reduces airway hyperresponsiveness, eosinophilia, mucus plugging, and asthma exacerbations, which are commonly caused by viral infections. Although clinical TSLP blockade attenuates virus-induced IL-33 and T2 cytokines in human bronchial epithelial cells (HBECs), the underlying mechanisms remain incompletely understood. Aim: The aim of this study was to identify transcriptomic changes modulated by tezepelumab in HBECs and determine their downstream remodelling-related effects on bronchial smooth muscle cells (BSMCs). Methods: HBECs from patients with uncontrolled asthma before and after 12 weeks of tezepelumab ( n = 13) or placebo ( n = 13) were expanded in vitro as submerged monocultures and subsequently exposed to poly(I:C). Transcriptomic profiling was performed, and selected targets were validated at mRNA and/or protein levels. Conditioned media from HBECs were applied to BSMCs to assess the expression of remodelling-associated mediators. Results: Tezepelumab treatment downregulated S100A8 and S100A9 expression in unstimulated HBECs. Following poly(I:C) stimulation, exploratory transcriptomic analysis identified enrichment of TNF-α/nuclear factor kappa B (NF-κB)-related pathways in placebo-treated HBECs compared with tezepelumab-treated HBECs. Validation analyses showed variable responses across the cohort, with attenuation observed primarily in patients with higher baseline inflammatory responses. In separate gain-of-function experiments, recombinant TSLP enhanced poly(I:C)-induced expression of S100A8, S100A9, TNFSF15, and TRAF1, together with increased NF-κB activation. Furthermore, conditioned media from poly(I:C)-stimulated HBECs collected after tezepelumab treatment induced lower TGF-β2 gene expression in BSMCs than conditioned media from placebo-treated HBECs. Conclusion: Clinical TSLP blockade by tezepelumab was associated with altered epithelial transcriptional responses and reduced TGF-β2 gene expression in BSMCs exposed to epithelial conditioned media. These findings are hypothesis-generating and provide transcriptional insight into the mechanisms underlying the therapeutic benefits in asthma management.

  • Open Access

    Glasmacinal enhances antiviral responses in bronchial epithelial cells from asthma patients

    by Sofia Malm Tillgren, Mandy Menzel, Jennifer A. Kricker, Michael J. Parnham, Virginia Norris, Maria Bech, Lena Uller

    Background: Macrolide antibiotics such as azithromycin (AZM) reduce asthma exacerbations and increase the antiviral defence of bronchial epithelial cells (BECs) from asthma patients. The chronic use of AZM has however raised concerns about antimicrobial resistance. A novel nonantibiotic macrolide, glasmacinal (EP395), is currently being developed as a possible treatment to reduce chronic respiratory disease exacerbations. In this study, we evaluated the effect of glasmacinal on rhinoviral (RV)-induced antiviral and pro-inflammatory genes in BECs from asthma patients. Methods: Primary BECs from asthma patients were pre-treated with AZM or glasmacinal for 24 h prior to infection with 0.05 multiplicity of infection RV1B for additional 24 or 48 h. Gene expression of interferon-β (IFN-β), melanoma differentiation-associated gene 5 (MDA5), retinoic acid-inducible gene I (RIG-I), tumour necrosis factor-α (TNF-α), interleukin (IL-6), IL-8, C-C motif chemokine ligand 20 (CCL20) and viral RNA was measured using reverse transcription quantitative PCR. As a marker of cell toxicity, lactate dehydrogenase (LDH) activity was measured in cell supernatants. Results: Glasmacinal dose-dependently increased RV-induced mRNA levels of IFN-β (p<0.05), with no additional LDH activity in cell supernatants. RV-induced mRNA expression of MDA5 and RIG-I were also significantly increased with glasmacinal treatment (p<0.05). Concomitantly, viral RNA was significantly reduced by glasmacinal treatment (p<0.01). There was no effect on the RV-induced expression of TNF-α, IL-6, IL-8 or CCL20. These effects were comparable to those of AZM. Conclusions: Glasmacinal enhances the antiviral IFN-β, MDA5 and RIG-I response and reduces viral load in BECs from asthma patients. The modulation of epithelial antiviral immunity suggests that glasmacinal may be beneficial in reducing viral-induced asthma exacerbations, although this requires validation in functional and clinical studies.

  • Open Access

    Mepolizumab Modifies Blood Eosinophil Proteome and Transcriptome in Severe Eosinophilic Asthma

    by Pablo Miguéns‐Suárez, Sara Vázquez‐Mera, Laura Martelo‐Vidal, Marina Blanco Aparicio, Uxío Calvo Álvarez, Coral González Fernández, Mar Mosteiro Añón, Dolores Corbacho Abelaira, Tamara Hermida Valverde, Christian Calvo Henríquez, et al.

    Background: Mepolizumab, an anti‐IL5 monoclonal antibody, effectively reduces exacerbations and improves disease control in severe eosinophilic asthma (SEA). While this treatment rapidly decreases blood eosinophil counts, some patients continue to experience asthma symptoms, suggesting that other features beyond eosinophil number contribute to disease persistence. In this work, we aim to characterize the molecular and functional signature of circulating eosinophils in SEA in response to mepolizumab therapy. Methods: We performed proteomic (LC–MS/MS) and targeted transcriptomic (Nanostring) analyses on isolated blood eosinophils from healthy individuals and SEA patients at baseline and after 4, 16 and 32 weeks of treatment with mepolizumab. Western blot was used to validate selected genes and proteins. Results: Eosinophils from healthy donors and post‐treatment SEA patients exhibit lower levels of proteins related to cytoskeleton (e.g., GSN, DBNL, ARPC2 and ARPC3), suggesting a lower potential for migration and tissue extravasation. Several proteins (e.g., EPX and NCF2) and genes (e.g., CCL23 and SOCS3) directly involved in eosinophil effector functions, including ROS generation and degranulation, were significantly downregulated after mepolizumab treatment. The downregulation of GSN (actin‐binding protein), NCF2 (subunit of the NADPH oxidase complex) and EPX (eosinophil‐specific granule protein), was further validated by western blot. Conclusions: Our multi‐omic analysis suggests that mepolizumab reduces the migratory capacity and effector‐related molecular signatures of circulating eosinophils in SEA patients. Selected proteins, including GSN, NCF2 and EPX, may serve as candidate biomarkers for monitoring response to therapy.

  • Open Access

    Chronic exposure to aerosolized PM2.5 in rats alters plasma protein levels and ex vivo coronary artery response to sphingosine-1-phosphate

    by Irma Mahmutovic Persson, Fanny Bergman, Lena Uller, Christina Isaxon, Lena Ohlsson

  • Open Access

    Chronic exposure to aerosolized PM2.5 in rats alters plasma protein levels and ex vivo coronary artery response to Sphingosine-1-phosphate

    by Irma Mahmutovic Persson, Fanny Bergman, Lena Uller, Christina Isaxon, Lena Ohlsson

    Growing evidence shows that air pollution exposure plays a critical role in the development and progression of cardiovascular disease. Pollutants such as airborne particles smaller than 2.5 µm (PM2.5) are linked to systemic inflammation, oxidative stress and vascular dysfunction, thereby increasing the risk of hypertension, atherosclerosis, stroke and myocardial infarction. Understanding the pathology and the disease progression is essential for developing targeted interventions to mitigate the global cardiovascular burden associated with polluted air. We aimed to study how different PM2.5 exposure regimes may affect vasomotor response in coronary arteries. Using well-characterized PM2.5 collected in an urban environment, we exposed rats to re-aerosolized PM2.5, mimicking different potential scenarios of air pollution exposures such as acute high-dose exposure compared to chronic exposure at a lower dose. Vascular tone was studied ex vivo from the PM2.5 exposed rats and their corresponding controls, employing a wire myograph. Also, systemic effects were assessed through plasma biomarkers of soluble Sphingosine-1-phosphate (S1P) and Endothelin-1 (ET-1) together with immunohistochemical assessment of coronary arteries. In our translational experimental set-up, we observed that only the accumulative dose from the chronic exposure played a significant role on the studied outcomes in the vasculature and plasma biomarkers. Following chronic exposure, S1P vasomotor response was altered in coronary arteries, as well as plasma total protein levels and ET-1 concentration, which were significantly decreased. This indicates the importance of prolonged PM2.5 exposure effects on cardiovascular health, highlighting medical intervention options alongside the importance of improving air pollution management.

  • Open Access

    Antimicrobial peptide LL-37 increases rhinovirus-induced interferon β expression in human airway epithelial cells through a Ca2+-dependent mechanism

    by Samuel Cerps, Sangeetha Ramu, Olof Gidlöf, Mandy Menzel, Karl Swärd, Lena Uller, Bengt-Olof Nilsson

  • Open Access

    T2 cytokine-driven alarmin and antiviral responses in asthma: insights into immune modulation and the role of IL-4Rα targeting

    by Jelena Pesic, Juan José Nieto-Fontarigo, Katerina Pardali, Stephen Delaney, Henric Olsson, Lena Uller

    Introduction: Severe asthma is a heterogeneous condition characterized by distinct phenotypes and endotypes based on clinical or biological characteristics. Interleukin (IL) 4 and IL-13 are central cytokines in the type 2 (T2) immune response, crucial for T2 inflammation. Biologic therapies targeting the IL-4/IL-13 pathway, such as anti-IL-4Rα monoclonal antibodies (mAbs), have shown improvements in lung function and reductions in exacerbation rates for severe asthma. However, the precise role of early innate immune responses in mediating these therapeutic benefits remains unclear. This study investigates the acute and chronic effects of T2 cytokines on healthy and asthmatic bronchial epithelial cells (BECs), addressing the mechanisms underlying IL-4Rα mAb therapy in acute T2-driven inflammatory conditions and rhinoviral infection in asthma BECs.Methods: Human BECs from healthy and asthma donors were cultured at the air–liquid interface (ALI) and stimulated with IL-4 and IL-13, acutely or chronically, with or without IL-4Rα mAb, followed by rhinovirus (RV) infection. Cells were harvested 24 h post-infection. Expression levels of chemokines, alarmins, and antiviral mediators were quantified using RT-qPCR and multiplex ELISA.Results: CCL26 expression increased in response to IL-4 or IL-13 in healthy and asthmatic BECs, and this effect was significantly more pronounced in asthmatic BECs. IL-4Rα mAb treatment effectively inhibited CCL26 production in BECs from asthma patients. IL-4 and RV infection induced a significant increase in thymic stromal lymphopoietin (TSLP) levels in BECs from asthma compared with healthy, which was normalized by IL-4Rα mAb. No significant effects of T2 cytokines on alarmins were observed in healthy BECs. Chronic exposure to T2 cytokines following RV infection significantly decreased TSLP and IFNλ1 but increased IFNβ, specifically in asthmatic BECs.Conclusions: Our study on T2 cytokines' effects on BECs reveals that asthma BECs have an increased inflammatory response to IL-4 and IL-13. These responses, marked by increased CCL26 and TSLP, were effectively mitigated by IL-4Rα mAb. Importantly, this treatment maintained essential antiviral defenses, such as IFNβ, even post-rhinoviral infection. Our results suggest a novel mechanism by which IL-4Rα mAb controls exacerbations and improves lung function.


  • Open Access

    Inhibition of IL-4Rα reduces CCL26 in bronchial epithelial cells from COPD patients

    by Jelena Pesic, Juan José Nieto Fontarigo, Sofia Malm Tillgren, Pablo Miguéns Suárez, Samuel Cerps, Katerina Pardali, Stephen Delaney, Lena Uller

    Background: Anti-IL-4Rα monoclonal antibodies (mAb) improve lung function and decrease the number of exacerbations in patients with COPD type (T) 2 inflammation. However, the involvement of early innate immune responses underlying these treatment effects is not well known. We sought to understand the effect and mechanisms of IL-4Rα mAb treatment on bronchial epithelial cells from COPD patients under T2 inflammatory conditions with and without rhinoviral infection.Methods: Primary bronchial epithelial cells (BECs) from healthy and COPD patients were grown at air–liquid interface (ALI) and stimulated with IL-4 or IL-13 cytokines in the presence of IL-4Rα mAb. Cells were infected with human rhinovirus 1B (HRV1B) and collected 24 h after infection. Anti-viral mediators (i.e., interferons (IFN) and pattern recognition receptors (PRR)), as well as chemokine and alarmin expression was measured by RT-qPCR and ELISA.Results: Treatment with IL-4Rα mAb (100 nM) inhibited eotaxin-3 (CCL26) gene after IL-4/IL-13 induction (p<0.05) in COPD BECs. However, no significant changes in RV-induced IFN-β, PRRs or TSLP gene responses were observed with IL-4/IL-13 stimulation and IL-4Rα mAb treatment. Significant increase in MUC5AC gene expression was observed with both IL-4 and IL-13 stimulation, but it was not reduced with IL-4Rα treatment in BECs.Conclusions: Inhibition of IL-4Rα reduced CCL26 levels without affecting anti-viral immune responses in bronchial epithelial cells from COPD patients. Inhibition of IL-4Rα reduced IL-4/IL-13 signaling without broadly suppressing the immune system, which might suggest that inhibition of the IL-4Rα pathways may prevent COPD exacerbations through reduction of eosinophil chemotaxis.


  • Open Access

    Signature Proteins in Small Extracellular Vesicles of Granulocytes and CD4+ T-Cell Subpopulations Identified by Comparative Proteomic Analysis

    by Sara Vázquez-Mera, Pablo Miguéns-Suárez, Laura Martelo-Vidal, Sara Rivas-López, Lena Uller, Susana B. Bravo, Vicente Domínguez-Arca, Xavier Muñoz, Francisco J. González-Barcala, Juan J. Nieto Fontarigo, et al.

    Several studies have described the proteomic profile of different immune cell types, but only a few have also analysed the content of their delivered small extracellular vesicles (sEVs). The aim of the present study was to compare the protein signature of sEVs delivered from granulocytes (i.e., neutrophils and eosinophils) and CD4+ T cells (i.e., TH1, TH2, and TH17) to identify potential biomarkers of the inflammatory profile in chronic inflammatory diseases. Qualitative (DDA) and quantitative (DIA-SWATH) analyses of in vitro-produced sEVs revealed proteome variations depending on the cell source. The main differences were found between granulocyte- and TH cell-derived sEVs, with a higher abundance of antimicrobial proteins (e.g., LCN2, LTF, MPO) in granulocyte-derived sEVs and an enrichment of ribosomal proteins (RPL and RPS proteins) in TH-derived sEVs. Additionally, we found differentially abundant proteins between neutrophil and eosinophil sEVs (e.g., ILF2, LTF, LCN2) and between sEVs from different TH subsets (e.g., ISG15, ITGA4, ITGB2, or NAMPT). A “proof-of-concept” assay was also performed, with TH2 biomarkers ITGA4 and ITGB2 displaying a differential abundance in sEVs from T2high and T2low asthma patients. Thus, our findings highlight the potential use of these sEVs as a source of biomarkers for diseases where the different immune cell subsets studied participate, particularly chronic inflammatory pathologies such as asthma or chronic obstructive pulmonary disease (COPD).


  • Open Access

    Phenotype and severity of asthma determines bronchial epithelial immune responses to a TLR3 agonist

    by Celeste Porsbjerg, Juan Nieto-Fontarigo, Samuel Cerps, Sangeetha Ramu, Mandy Menzel, Morten Hvidtfeldt, Silberbrandt A, Froessing L, Ditte Klein, Asger Sverrild, et al.

    Background Asthma is characterized by an aggravated immune response to respiratory viral infections: This phenomenon is a clinically well-recognized driver of acute exacerbations, but how different phenotypes of asthma respond immunologically to virus is unclear. Objectives To describe the association between different phenotypes and severity of asthma and bronchial epithelial immune responses to viral stimulation. Methods In the Immunoreact study, healthy subjects (n=10) and 50 patients with asthma were included; 30 (60%) were atopic, and 34 (68%) were eosinophilic; 15 (25%) had severe asthma. All participants underwent bronchoscopy with collection of bronchial brushings. Bronchial epithelial cells (BECs) were expanded and stimulated with the viral replication mimic poly (I:C) (TLR3 agonist) in vitro . The expression of TLR3-induced pro-inflammatory and anti-viral responses of BECs were analyzed using RT-qPCR and multiplex ELISA and compared across asthma phenotypes and severity of disease. Results Patients with atopic asthma had increased production of IL-4, IFN-β, IL-6, TNF-α, and IL-1β after poly (I:C) stimulation compared to non-atopic patients, whereas patients with eosinophilic asthma and non-eosinophilic asthma did not differ in the response to poly (I:C). Patients with severe asthma displayed a decreased antiviral IFN-β, and increased expression of IL-8, most pronounced in atopic and eosinophilic asthmatics. Interestingly, release of IL-33 and TSLP in response to poly (I:C) was increased in severe eosinophilic asthma, but not in severe atopic asthma. Conclusions The bronchial epithelial immune response to a viral mimic stimulation differs between asthma phenotypes and severities, which may be important to consider when targeting novel asthma treatments.